ArticleBMC medicine2023

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.

Yaxin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.